This assumption aligns with Tijink et al., who observed identical tumor accumulation between cetuximab and a Nanobody trimer involving two binding sites for EGFR and one binding site for albumin, but at different timelines, as the Nanobody trimer showed faster and deeper tumor accumulation than the antibody [25]. The gene discussed is EGFR; the disease is neoplasm.